{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-001004","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.572798+00:00","generated_at":"2026-05-16T11:15:20.105674+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Indaptus Therapeutics appoints David Natan to board and audit committee","bullets":["Board increased from 8 to 9 members; David Natan appointed as Class II director until 2026 annual meeting.","Natan replaces Avraham Ben-Tzvi as Audit Committee member; Ben-Tzvi to become paid consultant while remaining on board.","Natan was designated by David E. Lazar under securities purchase agreement dated December 22, 2025.","Natan is CPA and CEO of Natan & Associates; also serves on boards of Sunshine Biopharma and FIEE."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-001004","json":"https://secwatch.observer/filing/0001493152-26-001004.json","markdown":"https://secwatch.observer/filing/0001493152-26-001004.md","text":"https://secwatch.observer/filing/0001493152-26-001004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/0001493152-26-001004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226001004/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:15:20.105674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}